Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

308
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
308
Modified-Release Drug Delivery Systems: Bioavailability01:30

Modified-Release Drug Delivery Systems: Bioavailability

108
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
108
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

243
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
243
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

216
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
216
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism01:21

Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism

835
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
835
Drug Delivery Systems: Different Types01:27

Drug Delivery Systems: Different Types

235
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
235

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RETRACTED: Bakshi et al. Crocin Inhibits Angiogenesis and Metastasis in Colon Cancer via TNF-α/NF-kB/VEGF Pathways. <i>Cells</i> 2022, <i>11</i>, 1502.

Cells·2026
Same author

Metformin as a Metabolic Reprogramming Interface in Host-Pathogen and Bone Microenvironment Crosstalk: A Dual-Target Strategy Against Antimicrobial Resistance and Osteoporotic Bone Loss.

Antibiotics (Basel, Switzerland)·2026
Same author

Harnessing Machine Learning for Accelerated Drug Discovery: Opportunities and Unmet Challenges.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Pharmacogenomic Stratification for Oncology Drug Repurposing: An Exposure Target Context Eligibility Framework.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Plant-Derived Polyphenols in Cancer Therapy: Bridging Molecular Mechanisms and Bioavailability Toward Clinical Translation.

Pharmaceutics·2026
Same author

Pharmacogenomics and Epigenetic Regulation Transforming Pediatric Precision Therapeutics.

Journal of personalized medicine·2026

Related Experiment Video

Updated: Mar 29, 2026

Synthesis and Characterization of mRNA-Loaded PolyBeta Aminoesters Nanoparticles for Vaccination Purposes
08:27

Synthesis and Characterization of mRNA-Loaded PolyBeta Aminoesters Nanoparticles for Vaccination Purposes

Published on: August 13, 2021

5.2K

Ambient-Stable mRNA Medicines: Emerging Paradigms in Dry and Solid-State Formulation.

Mohamed El-Tanani1, Syed Arman Rabbani1, Adil Farooq Wali1

  • 1RAK College of Pharmacy, Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah 11172, United Arab Emirates.

Pharmaceuticals (Basel, Switzerland)
|March 28, 2026
PubMed
Summary
This summary is machine-generated.

Messenger RNA (mRNA) therapeutics face cold-chain challenges. This review explores strategies for stable mRNA formulations, aiming for room-temperature storage and global accessibility.

Keywords:
ambient stabilitylipid nanoparticleslyophilizationmRNA therapeuticspredictive designsolid-state formulation

More Related Videos

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells
10:02

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Published on: June 10, 2022

2.8K
Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA
08:29

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA

Published on: February 1, 2019

10.7K

Related Experiment Videos

Last Updated: Mar 29, 2026

Synthesis and Characterization of mRNA-Loaded PolyBeta Aminoesters Nanoparticles for Vaccination Purposes
08:27

Synthesis and Characterization of mRNA-Loaded PolyBeta Aminoesters Nanoparticles for Vaccination Purposes

Published on: August 13, 2021

5.2K
Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells
10:02

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Published on: June 10, 2022

2.8K
Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA
08:29

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA

Published on: February 1, 2019

10.7K

Area of Science:

  • Biotechnology
  • Pharmaceutical Sciences
  • Materials Engineering

Background:

  • Messenger RNA (mRNA) therapeutics offer programmable treatment options via versatile vaccination platforms.
  • Widespread adoption is hindered by extreme cold storage and transportation requirements, posing a significant challenge.
  • mRNA stability is a critical scientific and industrial hurdle demanding innovation in formulation and engineering.

Purpose of the Study:

  • To review current knowledge and novel methods for enhancing mRNA stability and achieving cold-chain independence.
  • To explore advanced mRNA development strategies and assess manufacturing, regulatory, and logistical obstacles.
  • To present a pathway for developing stable mRNA medicines effective at ambient temperatures (25°C and above).

Main Methods:

  • Assessment of RNA hydrolysis, lipid oxidation, and water-mediated degradation mechanisms.
  • Evaluation of solid-state stabilization techniques including lyophilization, spray-freeze-drying, and thin-film technologies.
  • Analysis of advanced mRNA structures (self-amplifying, circular RNA) and novel materials (nano-glass, MOFs), alongside AI-driven design.

Main Results:

  • Vitrification, water replacement, and excipient-RNA interactions are key mechanisms for enhancing stability.
  • Solid-state stabilization methods and advanced materials show promise for room-temperature formulations.
  • Manufacturing, quality control, packaging, and environmental testing are crucial for real-world implementation.

Conclusions:

  • Merging formulation design, process control, and material engineering is essential for cold-chain independent mRNA therapeutics.
  • Advanced strategies and addressing logistical hurdles can enable mRNA medicines to maintain efficacy at ambient temperatures.
  • Developing mRNA into a durable therapeutic platform requires integrating molecular research, process development, and regulatory standardization for global access.